November 13, 2024
2 min watch
Save
VIDEO: Oral Stargardt’s disease treatment focuses on reducing vitamin A dimerization
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company’s oral therapy for the treatment of Stargardt’s disease and age-related macular degeneration.
ALK-001 (gildeuretinol) is “a new chemical entity designed to lower dimerization in the retina and do so without modulating the visual cycle,” he said.
Dahan also discussed a trial investigating the oral treatment for geographic atrophy.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Dahan reports being the CEO of Alkeus Pharmaceuticals.
Read more about